WO1992019970A1 - Methode de detection et de traitement des maladies causees par des allergenes bacteriens - Google Patents
Methode de detection et de traitement des maladies causees par des allergenes bacteriens Download PDFInfo
- Publication number
- WO1992019970A1 WO1992019970A1 PCT/US1992/003284 US9203284W WO9219970A1 WO 1992019970 A1 WO1992019970 A1 WO 1992019970A1 US 9203284 W US9203284 W US 9203284W WO 9219970 A1 WO9219970 A1 WO 9219970A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pylori
- composition
- allergen
- protein
- ige
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 24
- 201000010099 disease Diseases 0.000 title claims description 22
- 239000013570 bacterial allergen Substances 0.000 title claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 88
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 88
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 59
- 229920001184 polypeptide Polymers 0.000 claims abstract description 58
- 239000012472 biological sample Substances 0.000 claims abstract description 6
- 239000013566 allergen Substances 0.000 claims description 96
- 239000000203 mixture Substances 0.000 claims description 52
- 210000002966 serum Anatomy 0.000 claims description 42
- 208000007882 Gastritis Diseases 0.000 claims description 24
- 206010020751 Hypersensitivity Diseases 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 17
- 241000894006 Bacteria Species 0.000 claims description 15
- 230000002163 immunogen Effects 0.000 claims description 14
- 230000003302 anti-idiotype Effects 0.000 claims description 12
- 230000001900 immune effect Effects 0.000 claims description 12
- 208000026935 allergic disease Diseases 0.000 claims description 10
- 208000030961 allergic reaction Diseases 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 7
- 108010032595 Antibody Binding Sites Proteins 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 239000010267 Allergoid Substances 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 241000589989 Helicobacter Species 0.000 claims 1
- 238000005349 anion exchange Methods 0.000 claims 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 14
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 238000009169 immunotherapy Methods 0.000 abstract description 6
- 238000003556 assay Methods 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 3
- 208000012895 Gastric disease Diseases 0.000 abstract description 2
- 229960004784 allergens Drugs 0.000 description 45
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 12
- 208000008469 Peptic Ulcer Diseases 0.000 description 10
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 9
- 208000023652 chronic gastritis Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000009257 reactivity Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 6
- -1 for example Chemical class 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 208000011906 peptic ulcer disease Diseases 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000589562 Brucella Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000001839 endoscopy Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000005201 scrubbing Methods 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010017865 Gastritis erosive Diseases 0.000 description 2
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 229940124452 immunizing agent Drugs 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- SVDJODOKSJEKEI-XAHCXIQSSA-N (4r)-5-amino-4-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-5-oxopentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(N)=O)CCC(O)=O SVDJODOKSJEKEI-XAHCXIQSSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 241000226657 Clarkia concinna Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000037446 allergic sensitization Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56922—Campylobacter
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
Definitions
- This invention is related to the field of allergens, more specifically to the identification of bacterial allergens, and to their use in disease diagnosis and treatment.
- a number of idiopathic recurrent diseases are of unknown etiology. Some of these diseases are thought to be linked to infection by a microorganism. However, the-causal relationship between the microorganism and the disease is often not established. The twin disorders of chronic gastritis and peptic ulcer disease are within this category.
- Chronic gastritis and peptic ulcer disease are diseases of major significance. Five to ten percent of all individuals develop chronic gastritis and or gastroduodenal ulcers in their lifetime. Ulcer disease is a common cause of morbidity. The annual prevalence of symptomatic peptic ulcer disease in the United States of America is approximately 18 per 1,000 adults (or 4,500,000 people). Approximately 350,000 new cases of peptic ulcer disease are diagnosed each year.
- Diagnosis of these diseases is usually performed by gastroduodenal endoscopy, an invasive and costly procedure. Treatment encompasses oral medication, dietary controls, and surgery. Rarely is it definitive, and these chronic conditions often have cycles of improvement and relapse.
- the identification of protein allergens of H. pylori associated with gastritis/ulcer disease allows for a relatively non-invasive detection of the disease by a modified RAST test. It also allows for treatment of the disease by immunotherapy, using purified protein allergens.
- one aspect of the invention is a method of measuring IgE which binds immunologically to a bacterial allergen.
- Serum suspected of containing the IgE is reacted with an extract of the bacteria coupled to a solid support, followed by washing and reacting with labelled anti-IgE, and detecting labeled anti-IgE bound to the solid support, the improvement comprising reacting the serum with a composition capable of removing IgA and IgG from the serum prior to the reacting with the bacterial extract coupled to the solid support, wherein the amount of composition used is sufficient to remove IgA and IgG which interferes with the IgE binding to the bacterial allergen.
- Another aspect of the invention is a method of preparing purified protein allergen from bacteria comprising: (a) treating bacteria containing a protein allergen with acetone to remove lipid components; (b) disrupting the acetone-treated bacteria in a solution comprised of buffer, salt, metal chelator, protease inhibitor, and benazamidine; (c) separating a protein containing fraction from complex carbohydrates and nucleic acids; (d) collecting a composition comprised of proteins which are of molecular weight at least about 5 1,000; and (e) separating the proteins of the composition of (d) by ion-exchange chromatography.
- Still another aspect of the invention an immunotherapeutic method of treating an individual for a disease resulting from an allergic reaction to a
- Another aspect of the invention is a method of determining whether an individual has an allergic response to Helicobacter pylori, the method comprising: (a) providing serum from an individual suspected of containing IgE to H. pylori allergens; (b) providing a
- composition consisting essentially of H. pylori protein allergens; (c) reacting the serum of (a) with the composition of (b) under conditions which allow immunological binding between IgE and an allergen to which it is directed; and (d)detecting IgE-allergen
- Still another aspect of the invention is a composition consisting essentially of protein allergens of H. pylori.
- Another aspect of the invention is a protein allergen of H. pylori coupled to a solid substrate.
- Yet another aspect of the invention is a method of treating an individual for H. pylori induced gastritis comprising introducing into the individual a composition comprised of a polypeptide which contains one or more epitopes that are immunologically identifiable with immunogenic epitopes of H. pylori, wherein the polypeptide is in an amount sufficient to relieve an allergic reaction to H. pylori in the individual, and wherein the composition is further comprised of a suitable excipient.
- Still another aspect of the invention is a diagnostic kit comprised of a polypeptide containing at least one epitope which is immunologically identifiable with an H. pylori epitope, packaged in a suitable container, and a means for detecting immunological complexes formed between the polypeptide and IgE in the biological sample, if any.
- compositions comprised of a structural analog of an epitope of an H. pylori allergen, wherein the structural analog binds to an IgE paratope.
- compositions comprised of a purified polyclonal antibody directed to a polypeptide allergen of H. pylori.
- composition comprised of a monoclonal antibody directed to a polypeptide allergen of H. pylori.
- Figure 1 is a graph showing the effect of scrubbing serum with Protein A on the detection of anti- 3 pylori IgE in a modified RAST test.
- Figure 2A is a graph showing the serum IgE levels of IgE directed to subfractions of 2£. pylori protein allergens in healthy individuals (controls) .
- Figure 2B is a graph showing the serum IgE levels of IgE directed to subfractions of H. pylori protein allergens in gastritis patients.
- Figure 3 is a plot of the net total IgE immunological reactivity of serum from control and gastritis patients using all available H. pylori protein fractions isolated from an HPLC DEAE column.
- Figure 4 is a plot of the net total IgE immunological reactivity of serum from control and gastritis patients with the proteins in fractions 59, 64, 66, 68, 72 and 74 of the HPLC DEAE column.
- the present invention stems from the discovery that individuals with chronic gastritis or gastroduodenal ulcers have serum IgE specific for protein allergens of H. pylori, implicating hypersensitivity to this microorganism in the etiology of the diseases.
- H. pylori is most likely an innocuous colonizer of the gastric mucosa. It dwells just beneath the protective mucous layer and probably feeds from it without much harm to the host or to the host's protective defenses against the gastric acid.
- the inflammatory process recognized in chronic gastrtitis results in those individuals who possess the genetic proclivity toward allergy and then have the necessary MHC II antigen framework for presenting the H. pylori allergenic proteins as allergens.
- a qualitative and/or quantitative reduction in the secretion of protective mucus by the goblet cells probably occurs thus making the underlying mucosa vulnerable.
- immunoassays to detect an H. pylori induced allergic reaction in individuals.
- these immunoassays utilize purified protein allergens, and are preferable to endoscopy since they may be performed in vitro and are relatively non-invasive.
- the discovery allows for a novel treatment of these diseases; i.e., immunotherapy with compositions comprised of at least one purified protein allergen of H. pylori. and/or with an allergoid of a protein allergen of H. pylori. 15
- the practice of the present invention will employ, unless otherwise indicated, conventional techniques of protein purification, microbiology, molecular biology, and immunology, which are within the skill of the art. Such techniques are explained fully in
- allergen refers to an antigen that gives rise to allergic sensitization by IgE antibodies.
- allergoid refers to a chemically
- the term "individual”, as used herein, refers to a vertebrate, particularly members of the mammalian species, and includes but is not limited to domestic
- allergy denotes an altered state of immune reactivity, usually denoting hypersensitivity.
- Immunologically identifiable 35_ with/as refers to the presence of epitope(s) and polypeptides(s) which are also present in the designated polypeptide(s) . Immunological identity may be determined by antibody binding and/or competition in binding; these techniques are known to those of average skill in the art, and are also illustrated infra.
- epitope refers to an antigenic determinant of a polypeptide.
- An epitope could comprise 3 amino acids in a spatial conformation which is unique to the epitope. Generally an epitope consists of at least 5 such amino acids, and more usually, consists of at least 8-10 such amino acids.
- Methods of determining the spatial conformation of amino acids are known in the art, and include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance.
- a polypeptide is "immunoreactive" when it is “immunologically reactive” with an antibody, i.e., when it binds to an antibody due to antibody recognition of a specific epitope contained within the polypeptide. Immunological reactivity may be determined by antibody binding, more particularly by the kinetics of antibody binding, and/or by competition in binding using as competitor(s) a known polypeptide(s) containing an epitope against which the antibody is directed. The techniques for determining whether a polypeptide is immunologically reactive with an antibody are known in the art.
- An “immunoreactive" polypeptide may also be “immunogenic".
- the term “immunogenic polypeptide” is a polypeptide that elicits a cellular and/or humoral immune response, whether alone or linked to a carrier in the presence or absence of an adjuvant.
- an antibody refers to a polypeptide or group of polypeptides which are comprised of at least one antibody combining site.
- An antibody combining site may be formed from a heavy and/or a light chain domain (VH and VL, respectively) , which form hypervariable loops which contribute to antigen binding.
- a “paratope” is an antibody combining site for an epitope, the simplest form of an antigenic determinant.
- antibody includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, altered antibodies, univalent antibodies, the Fab proteins, and single domain antibodies.
- polypeptide refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.
- polypeptide does not connote the method by which the molecule was made, and thus includes naturally occurring molecules, as well as molecules made by chemical or recombinant synthesis.
- a "biological sample” refers to a sample of tissue or fluid isolated from an individual, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs, and also samples of in vitro cell culture constituents.
- Coupled refers to attachment by covalent bonds or by strong non-covalent interactions (e.g., hydrophobic interactions, hydrogen
- Covalent bonds may be, for example, ester, ether, phosphoester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like.
- support refers to any solid or semi- solid surface to which a desired polypeptide.
- 15 supports include glass, plastic, metal, polymer gels, an the like, and may take the form of beads, wells, dipsticks, membranes, and the like.
- label refers to any atom or moiety which can be used to provide a detectable ,_ (preferably quantifiable) signal, and which can be attached to a polynucleotide or polypeptide.
- treatment refers to prophylaxis and/or therapy.
- immunogenic refers to an agent used
- an individual's allergic sensitivity to H. pylori is
- IgE 30 determined by detecting IgE specific to g. pylori allergens. Any method of detecting IgE specific for an allergen known in the art may be used.
- one or more polypeptides comprised of epitopes immunologically
- 3-5.. identifiable with epitopes of allergens are coupled to a solid substrate.
- a biological sample suspected of containing IgE specific for allergens from the material is reacted with the allergen-substrate complex, and IgE that reacted immunologically with the allergen of the complex is detected.
- An example of this kind of assay is the Radioallergosorbent (RAST) test.
- an allergen extract is coupled to cellulose particles or paper discs.
- Patient's serum containing IgE antibody or a standard serum is reacted with the allergen-coupled immunosorbent.
- labeled anti-IgE is reacted with the immunosorbent.
- the label on the ' separated sorbent is determined and is a measure of the amount of specific serum IgE antibodies to that allergen.
- the RAST test is modified to increase its sensitivity by removing IgG and/or IgA antibodies which may interfere with IgE binding to the allergen. This is particularly critical when measuring serum IgE specific to H. pylori allergens.
- Reactants capable of remvoving IgG and/or IgA are known in the art, and include, for example. Protein G, anti-human IgG and anti-human IgA, as well as Protein A. For convenience, these reactants may be affixed to a solid substrate, including, for example, Sepharose. The amount of the reactants used is sufficient to removing interfering IgG and IgA, but not the IgE which is to be detected. The determination of the desired amount is by methods known to those of skill in the art.
- a method of removing interfering IgG and/or IgA antibodies by incubation of the serum with Protein A is discussed in the Examples, infra. Generally, the amount of Protein A which is used is sufficient to prevent the blocking antibodies from competing with the IgE having the same specificity.
- the modified RAST test may also include the use _ of purified protein allergens.
- Methods of purifying proteins are known in the art, and include, for example, differential extraction, salt fractionation, chromatography on ion exchange resins, affinity chromatography, centrifugation, and the like. See, for Q example, Methods in Enzymology for a variety of methods for purifying proteins.
- An example of a purification procedure which separates protein allergens of H. pylori from carbohydrates, lipids, and nucleic acids is presented in the Examples.
- polypeptides comprised of one or more epitopes which are immunologically identifiable with epitopes of H. pylori allergens may be packaged in diagnostic kits.
- Diagnostic kits include the polypeptides in suitable containers and a means for detecting immunological complexes formed between the polypeptide and IgE in the biological sample, if any.
- the polypeptides may be affixed to a solid 0 substrate.
- the kit may also contain other suitably packaged reagents and materials needed for the particular diagnostic protocol, for example, standards, buffers, as well as instructions for conducting the test using the kit ingredients.
- individuals suspected of having a propensity for, or suffering from H are suspected of having a propensity for, or suffering from H.
- pylori induced gastric disease are treated with substances which reduce the allergic response to the microorganism.
- Treatment may be with, for example, a composition containing purified protein allergens, or with recombinant polypeptides or anti- idiotype antibodies which are immunologically identifiable with the protein allergen by virtue of one or more immunogenic epitopes which are immunologically cross-reactive with those on H. pylori protein allergen.
- One or more allergens contained within DEAE fractions 59, 64, 66, 68, 72 and 74, the preparation of which is described in Example 1, may be particularly suitable.
- Treatment may also be with, for example, allergoids of H.. pylori protein allergens.
- Methods of preparing allergoids from antigens are known in the art.
- mild formalin or glutaraldehyde treatment of the antigen reduces the allergenicity (IgE formation) without affecting the antigenicity (IgG "blocking" antibody formation) .
- Treatment may also be with, for example, compositions containing at least one structural analog of an epitope of a protein allergen, which binds to the corresponding IgE paratope.
- Structural analogs are organic molecules which are capable of assuming the appropriate charge distribution and hydrophobic/hydrophilic characteristics to allow binding to the paratope in a fashion which mimics the immunologic binding of the epitope.
- the treated individual receives injections of a composition comprised of one or more relevant allergens continuously.
- Treatment is begun at a dosage low enough to avoid any local or systemic reactions, and frequent injections, usually once or twice a week are administered at increasing dosages until the highest dose the patient can tolerate without excessive local or systemic reactions is reached.
- This is a maintenance dose, which is then continued at less frequent intervals, usually every 2-6 weeks depending upon the individual's response.
- the actual dosage and treatment regimen will depend upon the individual treated, and will be determined by the person administering the treatment.
- the immunoreactive polypeptides are prepared into vaccines.
- Vaccines may be prepared from one or more immunogenic polypeptides. If recombinant, these polypeptides may be expressed in a variety of host cells (e.g., bacteria, yeast, insect, or mammalian cells), or alternatively may be isolated from the bacterial preparations.
- vaccines which contain an immunogenic polypeptide(s) or structural analogs of epitopes as active ingredients, is known to one skilled in the art.
- such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared.
- the preparation may also be emulsified, or the protein encapsulated in liposomes.
- the active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or.the like and combinations thereof.
- the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.
- auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.
- adjuvants which may be effective include but are not limited to: aluminum hydroxide, N-acetyl-muramyl-
- thr-MDP L-threonyl-D-isoglutamine
- CGP 11637 N-acetyl-nor- muramyl-L-alanyl-D-isoglutamine
- nor-MDP N-acetylmuramyl-L-alanyl-D-isoglutaminyl- L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosph oryloxy)-ethylamine
- CGP 19835A referred to as MTP-PE
- RIBI which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion.
- the effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against an immunogenic polypeptide containing an H. p
- the vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly.
- Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations.
- suppositories traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably l%-2%.
- Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, .sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspen ⁇ sions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25%-70%.
- the proteins may be formulated into the vaccine as neutral or salt forms.
- Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
- the vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective.
- the quantity to be administered which is generally in the range of about 5 micrograms to about 250 micrograms of antigen per dose, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered may depend on the judgment of the practitioner and may be peculiar to each subject.
- the vaccine may be given in a single dose schedule, or preferably in a multiple dose schedule.
- a multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reenforce the immune response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months.
- the dosage regimen will also, at least in part, be determined by the need of the individual and be dependent upon the judgment of the practitioner.
- a polypeptide containing one or more epitopes immunologically identifiable with epitopes of an H. pylori allergen are used to prepare antibodies to H. pylori epitopes, using the polypeptide as an immunizing agent, and methods known to those of skill in the art.
- the antibodies prepared may be purified polyclonal antibodies, single-chain antibodies, monoclonal antibodies, antibody fragments, and the like. These antibodies may be used, for example, for purification by affinity chromatography polypeptides of interest. More specifically, they can be used to purify polypeptides containing epitopes immunologically identifiable with epitopes of fl. pylori allergens, including the allergens themselves.
- antibodies to H. pylori epitopes may be used for the preparation of anti-idiotype antibodies.
- These anti-idiotype antibodies are comprised of a region which mimics the epitope of the allergen.
- Anti-idiotype may be synthesized using methods known in the art, and will usually use antibodies directed to fl. oylori epitopes as an immunizing agent.
- Anti-idiotype antibodies may be useful in immunotherapy of individuals sensitive to fl. pylori allergens, as well as for the purification of and/or detection of antibodies directed to fl. pylori antigens containing epitopes which immunologically cross-react with the anti-idiotype antibodies.
- the immunogenic polypeptides prepared as described above are used to produce antibodies, including polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal (e.g., mouse, rabbit, goat, horse, etc.) is immunized with an immunogenic polypeptide bearing an H. pylori epitope(s). Serum from the im ⁇ munized animal is collected and treated according to known procedures.
- polyclonal antibodies to an H. pylori epitope contains antibodies to other antigens
- the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987) IMMUNOCHEMICAL METHODS IN CELL /ND MOLECULAR BIOLOGY (Academic Press, London) .
- polyclonal antibodies may be isolated from an individual previously infected with fl. pylori. and purified by the methods discussed above.
- Monoclonal antibodies directed against fl. pylori epitopes can also be readily produced by one skilled in the art.
- the general methodology for making monoclonal antibodies by hybridomas is well known.
- Im ⁇ mortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al. (1980) HYBRIDOMA TECHNIQUES PRINCIPLES AND PRACTICE, SECOND EDITION (Springer-Verlag, N.Y.).; Hammerling et al.
- Antibodies both monoclonal and polyclonal, which are directed against H. pylori epitopes are particularly useful in diagnosis, and those which are neutralizing are useful in passive immunotherapy.
- Monoclonal antibodies may be used to raise anti-idiotype antibodies.
- Anti-idiotype antibodies are immunoglobulins which carry an "internal image" of the antigen of the infectious agent against which protection is desired.
- anti-idiotype antibodies may also be useful for treatment, vaccination and/or diagnosis of H. pylori induced gastritis and/or gastroduodenal ulcers, as well as for an elucidation of the immunogenic regions of H. pylori antigens
- H. pylori ATCC strain 43504; ATCC, Bethesda, MD, USA
- H. pylori obtained from the American Type Culture Collection, ATCC No. 43504, was removed aspectically from its vial, suspended in 1 ml sterile Difco Brucella broth, and transferred by an in inoculating loop to 3 separate Brucella Agar plates (Anaerobe systems, San Jose, CA) .
- the plates were incubated at 35 deg C for 5 days in a microaerophilic atmosphere of 85% N,, 10% CO., and 5% 0,. After incubation the plates were removed and examined. Tiny grayish-white colonies were observed. Microscopic examination of a Gram-stained smear showed large oxbow- shaped and loops of Gram-negative rods (5 microns) , which are typical of H. pylori. fl. pylori in colonies from the 5 day plates were transferred to a fresh set of Brucella plates, and the plates were incubated microaerophilically at 35 deg C for 3 to 5 days. After 3 days a more luxuriant growth of H. pylori colonies occurred. These colonies were used as the inoculum for a broth seed culture.
- a broth seed culture was prepared by transferring to several 10 ml screw-capped tubes 5 ml sterile Brucella broth with 5% horse serum (GIBCO BRL) , and colonies collected by swab from the plates. All tubes were incubated at 35 deg C under a microaerophilic atmosphere for 3 to 5 days. If a heavy degree of turbidity was observed in the tubes after this period, the culture was examined for purity by microscopic examination of a Gram stained slide. The broth seed culture was used as an inoculum for one liter of sterile Difco Brucella broth containing 5% horse serum.
- the inoculated culture was grown in a 3 liter flask by incubation at 35 deg C in a microaerophilic atmosphere for 3 to 5 days. When a moderate degree of turbidity was observed, the culture was checked for purity as described above. One liter of culture generally yielded an unwashed cell amount of about 2.0 grams.
- the living organisms from the liter culture were pelleted by centrifugation at 3,000 RPM, 4 deg C for 15 minutes. They were attenuated and grossly defatted by suspension and vortexing in ice cold acetone for 15 minutes. The attenuated bacteria was then repelleted by similar centrifugation. The pellet was resuspended in 20 ml of cold buffer containing 50 mM sodium phosphate, pH 7.3, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 100 micrograms/ml PMSF and 100 micrograms/ml of benza idine. Ten mL or 150-210 micron, acid washed glass beads (Sigma, St.
- the supernatant was centrifuged for l hr at 100,000 g. 4 deg C, in a Beck an SW 40Ti rotor (Beckman, Palo Alto, CA, USA) . To the resulting supernatant was added 0.456 gm/ml of RbCl (Aldrich Chemical Co., Milwaukee, Wis. , USA). The solution was then centrifuged at 4 deg C for 48 hrs. in a Beckman 70 Ti rotor (the first 24 hrs at 65,000 RPM and the second 24 hrs at 48,000 RPM). The supernatant contents of each gradient tube were collected in ten equal fractions beginning at the bottom of each tube. The pellet in each tube representing most of the residual complex carbohydrates and nucleic acids containing in the pregradient supernatant was discarded.
- each gradient fraction was dialyzed against 20 mM sodium phosphate buffer, pH 7.0, at 4 deg C using dialysis tubing with a 1,000 MW cutoff. An approximation the protein content per fraction was made by ⁇ g spectrophotometry at a wavelength of 280 nm. Ninety percent of the detected protein was found in fractions 2 through 6, inclusive; these fractions were pooled. The pooled fractions were then loaded onto a Bio-Sil DEAE analytical anion exchange HPLC column (BioRad, Richmond,
- the equilibrating buffer (Buffer A) was 20 mM Sodium phosphate, pH 7.0.
- the salt containing buffer (Buffer B) was 20 mM sodium phosphate, pH 7.0, with 1.0 M NaCl.
- Example 2 A Modified RAST Procedure for Detecting IgE Specific to H. pylori Allergens
- IgE specific for H. pylori allergens was assayed for using a modified RAST procedure. Part of the procedure was essentially as described by Nalebuff et al. (Nalebuff et al., Otolarygol Head Neck Surg 89:271 (1981).). More specifically, an aliquot of 100 microliters of serum was incubated overnight with an appropriate allergen disc and washed three times with 50 mM phosphate buffered saline (PBS), pH 7.3, containing 0.1% Tween 20. This was followed by a second overnight incubation with I 125-labelled anti-IgE specific zor the
- De-2 determinant After being washed and prior to being counted, the allergen discs were placed into fresh tubes in a gamma counter for the amount of time previously selected by a time control.
- the time control consists of 25 units of WHO-standardization IgE that is run against a PRIST anti-IgE disc for the time needed for the IgE to bind 25,000 counts. This time is used in the counting of all subsequent tests.
- Scrubbing was by incubation with recombinant Protein A/Sepharose (Zymed, S. San Francisco, CA, USA) . More specifically, two ml of serum per one ml of Protein A/Sepharose were incubated with agitation for 1 hr. The suspension was then centrifuged at 1500 RPM for 15 min. and the serum supernatants collected.
- Figure 3 shows a plot of the net total IgE immunological reactivity of serum from control and gastritis patients using all available fl. pylori protein fractions isolated from an HPLC DEAE column.
- Figure 4 is a plot of the net total IgE immunological reactivity of serum from control and gastritis patients with the proteins in fractions 59, 62, 65, 70, 64, 68, 71, 73, and 74.
- Polypeptides containing one or more epitopes immunologically identifiable with epitopes of fl. pylori proteins are useful in the diagnosis of fl. pylori induced gastric diseases, and may also be useful for treatment of these diseases.
- These polypeptides are also useful for the production of antibodies, both purified polyclonal and monoclonal, directed towards epitopes of fl. pylori.
- the antibodies in their turn, are useful in the purification of polypeptides containing one or more epitopes immunologically identifiable with epitopes of fl. pylori proteins.
- Monoclonal antibodies are useful in the production of anti-idiotype antibodies, which in turn, are useful for the detection of antibodies containing specific epitopes of fl. pylori, and may also be useful in the production of vaccines for H. pylori induced diseases.
- the methods described herein use one or more polypeptides containing one or more epitopes of fl. pylori. and detect IgE directed to fl. pylori allergens. These methods, particularly the modified RAST method, are useful for the diagnosis of fl. pylori induced gastric diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20036/92A AU667040C (en) | 1991-04-26 | 1992-04-21 | Methods to detect and treat diseases caused by bacterial allergens |
JP4511878A JPH06507494A (ja) | 1991-04-26 | 1992-04-21 | 細菌性アレルゲンにより惹起される疾患の検出及び治療方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69323291A | 1991-04-26 | 1991-04-26 | |
US693,232 | 1991-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992019970A1 true WO1992019970A1 (fr) | 1992-11-12 |
Family
ID=24783856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/003284 WO1992019970A1 (fr) | 1991-04-26 | 1992-04-21 | Methode de detection et de traitement des maladies causees par des allergenes bacteriens |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0582672A4 (fr) |
JP (1) | JPH06507494A (fr) |
CA (1) | CA2109088A1 (fr) |
WO (1) | WO1992019970A1 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0590138A1 (fr) | 1992-04-13 | 1994-04-06 | Inc. Oravax | Traitement par voie orale de l'infection provoquee par l'helicobacter |
WO1994029696A1 (fr) * | 1993-06-09 | 1994-12-22 | Quidel Corporation | Titrages en une etape specifiques d'un antigene |
WO1995017677A1 (fr) * | 1993-12-20 | 1995-06-29 | Calenoff Emanuel J | Methodes et preparations pour le diagnostic et le traitement d'affections dues aux antigenes de micro-organismes |
WO1996012965A1 (fr) * | 1994-10-20 | 1996-05-02 | Genelabs Diagnostics Pte Ltd. | Methodes de diagnostic de l'helicobacter pylori et necessaires correspondants |
WO1996026740A1 (fr) * | 1995-02-27 | 1996-09-06 | Enteron Limited Partnership | Procedes et compositions de vaccins individualises contre les affections liees aux antigenes de micro-organismes |
US5871749A (en) * | 1993-07-27 | 1999-02-16 | Csl Limited | Therapeutic treatment of H. pylori associated gastroduodenal disease |
US5972336A (en) * | 1992-11-03 | 1999-10-26 | Oravax Merieux Co. | Urease-based vaccine against helicobacter infection |
US6406703B1 (en) | 1993-07-27 | 2002-06-18 | Csl Limited | Treatment of H. pylori associated gastroduodenal disease |
EP0794434A4 (fr) * | 1995-09-22 | 2003-06-11 | Asahi Denka Kogyo Kk | Procede d'analyse pour allergene |
EP1872792A1 (fr) * | 2006-06-29 | 2008-01-02 | Biotech Tools S.A. | Méthode pour la production d'un allergène hydrolysé |
RU2568242C2 (ru) * | 2012-04-24 | 2015-11-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им В.А. Энгельгарда Российской академии наук (ИМБ РАН) | Способ обработки образца крови при проведении иммунологического анализа аллерген-специфических и общих иммуноглобулинов е |
RU2587327C2 (ru) * | 2014-11-19 | 2016-06-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России) | Способ диагностики in vitro специфической сенсибилизации организма к бактериальным аллергенам |
US9884111B2 (en) | 2010-02-12 | 2018-02-06 | Laboratorios Leti, S.L. | Process for producing an allergen extract |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3983008A (en) * | 1974-05-27 | 1976-09-28 | Idemitsu Kosan Co., Ltd. | Method of extracting useful components from microbial cells |
EP0282018A2 (fr) * | 1987-03-13 | 1988-09-14 | Hoechst Aktiengesellschaft | Procédé pour isoler des protéines de membrane de base de tissus humains et animaux |
US4849337A (en) * | 1983-01-31 | 1989-07-18 | Minnesota Mining And Manufacturing Company | Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody |
US4870053A (en) * | 1980-09-19 | 1989-09-26 | Roussel Uclaf | Novel compositions and processes |
EP0451800A1 (fr) * | 1990-04-13 | 1991-10-16 | Abbott Laboratories | Attachement d'allergènes à une phase solide |
-
1992
- 1992-04-21 WO PCT/US1992/003284 patent/WO1992019970A1/fr not_active Application Discontinuation
- 1992-04-21 EP EP19920912647 patent/EP0582672A4/en not_active Withdrawn
- 1992-04-21 CA CA002109088A patent/CA2109088A1/fr not_active Abandoned
- 1992-04-21 JP JP4511878A patent/JPH06507494A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3983008A (en) * | 1974-05-27 | 1976-09-28 | Idemitsu Kosan Co., Ltd. | Method of extracting useful components from microbial cells |
US4870053A (en) * | 1980-09-19 | 1989-09-26 | Roussel Uclaf | Novel compositions and processes |
US4849337A (en) * | 1983-01-31 | 1989-07-18 | Minnesota Mining And Manufacturing Company | Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody |
EP0282018A2 (fr) * | 1987-03-13 | 1988-09-14 | Hoechst Aktiengesellschaft | Procédé pour isoler des protéines de membrane de base de tissus humains et animaux |
EP0451800A1 (fr) * | 1990-04-13 | 1991-10-16 | Abbott Laboratories | Attachement d'allergènes à une phase solide |
Non-Patent Citations (6)
Title |
---|
D.M. WEIR, "Handbook of Experimental Immunology", published 1978 by Blackwell Scientific Publications (Oxford), pages 2.1-2.17. * |
Gastroenterology, Volume 101, No. 1, issued July 1991, ACETI et al., "Basophil-Bound and Serum Immunoglobulin E Directed Against Helicobacteri pylori in Patients with Chronic Gastritis", pages 131-137, especially Abstract on page 131, page 133, left column, second full paragraph and page 136, left column first full paragraph. * |
Journal of Immunology, Volume 126, No. 2, issued February 1981, GLEICH et al., "Measurement of IgG Blocking Antibodies by Interference in the Radioallergosorbent Test", pages 575-579, Abstract on page 575 and page 578, lines 33-34. * |
See also references of EP0582672A4 * |
The New England Journal of Medicine, Volume 324, No. 15, issued 11 April 1991, PETERSON, "Helicobacter Pylori and Peptic Ulcer Disease", pages 1043-1048. * |
Trends in Biotechnology, Volume 3, No. 7, issued 1985, SCOTT, "Monoclonal antibodies-approaching adolescence in diagnostic immunoassays", pages 170-175. * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567594A (en) * | 1991-04-26 | 1996-10-22 | Enteron, L.P. | Methods and compositions for the detection and treatment of diseases associated with antigens of microorganisms |
US5538729A (en) * | 1992-04-13 | 1996-07-23 | Oravax, Inc. | Oral treatment of helicobacter infection |
EP0590138A1 (fr) | 1992-04-13 | 1994-04-06 | Inc. Oravax | Traitement par voie orale de l'infection provoquee par l'helicobacter |
US5972336A (en) * | 1992-11-03 | 1999-10-26 | Oravax Merieux Co. | Urease-based vaccine against helicobacter infection |
WO1994029696A1 (fr) * | 1993-06-09 | 1994-12-22 | Quidel Corporation | Titrages en une etape specifiques d'un antigene |
US6406703B1 (en) | 1993-07-27 | 2002-06-18 | Csl Limited | Treatment of H. pylori associated gastroduodenal disease |
US5871749A (en) * | 1993-07-27 | 1999-02-16 | Csl Limited | Therapeutic treatment of H. pylori associated gastroduodenal disease |
US6129923A (en) * | 1993-07-27 | 2000-10-10 | Csl Limited | Treatment of H. pylori associated gastroduodenal disease |
WO1995017677A1 (fr) * | 1993-12-20 | 1995-06-29 | Calenoff Emanuel J | Methodes et preparations pour le diagnostic et le traitement d'affections dues aux antigenes de micro-organismes |
WO1996012965A1 (fr) * | 1994-10-20 | 1996-05-02 | Genelabs Diagnostics Pte Ltd. | Methodes de diagnostic de l'helicobacter pylori et necessaires correspondants |
WO1996026740A1 (fr) * | 1995-02-27 | 1996-09-06 | Enteron Limited Partnership | Procedes et compositions de vaccins individualises contre les affections liees aux antigenes de micro-organismes |
EP0794434A4 (fr) * | 1995-09-22 | 2003-06-11 | Asahi Denka Kogyo Kk | Procede d'analyse pour allergene |
EP1872792A1 (fr) * | 2006-06-29 | 2008-01-02 | Biotech Tools S.A. | Méthode pour la production d'un allergène hydrolysé |
WO2008000783A1 (fr) * | 2006-06-29 | 2008-01-03 | Biotech Tools S.A. | Procédé de production d'un allergène hydrolysé |
EP3308799A1 (fr) * | 2006-06-29 | 2018-04-18 | ASIT BioTech S.A. | Procédé de production d'allergène hydrolysé |
US9884111B2 (en) | 2010-02-12 | 2018-02-06 | Laboratorios Leti, S.L. | Process for producing an allergen extract |
US11246923B2 (en) | 2010-02-12 | 2022-02-15 | Laboratorios Leti, S.L. Unipersonal | Process for producing an allergen extract |
RU2568242C2 (ru) * | 2012-04-24 | 2015-11-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им В.А. Энгельгарда Российской академии наук (ИМБ РАН) | Способ обработки образца крови при проведении иммунологического анализа аллерген-специфических и общих иммуноглобулинов е |
RU2587327C2 (ru) * | 2014-11-19 | 2016-06-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России) | Способ диагностики in vitro специфической сенсибилизации организма к бактериальным аллергенам |
Also Published As
Publication number | Publication date |
---|---|
EP0582672A4 (en) | 1994-06-29 |
AU2003692A (en) | 1992-12-21 |
CA2109088A1 (fr) | 1992-10-27 |
AU667040B2 (en) | 1996-03-07 |
JPH06507494A (ja) | 1994-08-25 |
EP0582672A1 (fr) | 1994-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5567594A (en) | Methods and compositions for the detection and treatment of diseases associated with antigens of microorganisms | |
Biberfeld | Antibodies to brain and other tissues in cases of Mycoplasma pneumoniae infection | |
US5262156A (en) | Antigenic compositions and their use for the detection of Helicobacter pylori | |
JP4295431B2 (ja) | 髄膜炎菌性bエピトープの分子模倣物 | |
US20080139789A1 (en) | Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection | |
WO1992019970A1 (fr) | Methode de detection et de traitement des maladies causees par des allergenes bacteriens | |
JP2002523019A (ja) | ワクチンとしてのボレリアブルグドルフェリ外部表面タンパク質c(ospc)のボレリアシダルエピトープの使用 | |
Frasch et al. | Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine | |
US7279162B1 (en) | Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection | |
Chen et al. | Studies on Immunization Against Plague: II. The Complement-Fixation Test | |
WO1995009181A1 (fr) | Peptide contenant une sequences d'acides amines de la proteine de franges de porphyromonas gingivalis, et utilisation dudit peptide | |
CN101981052B (zh) | 组合物、方法及试剂盒 | |
JP3767755B2 (ja) | 抗jcウイルス抗体 | |
JPH03500210A (ja) | 冠動脈性心臓病の治療および診断のための方法 | |
Relyveld et al. | Antibody response of pregnant women to two different adsorbed tetanus toxoids | |
US3992516A (en) | Direct fluorescent antibody composition and method for P. Pneumocystis carinii | |
US4696896A (en) | Gonococcal Pili processes for the preparation thereof and the use thereof for the detection of and prevention of infections caused by Neisseria gonorrhoeae | |
US4461838A (en) | Gonococcal Pili processes for the preparation thereof and the use thereof for the detection of and prevention of infections caused by Neisseria gonorrhoeae | |
AU667040C (en) | Methods to detect and treat diseases caused by bacterial allergens | |
WO1996026740A1 (fr) | Procedes et compositions de vaccins individualises contre les affections liees aux antigenes de micro-organismes | |
CA2200691C (fr) | Anticorps a activite opsonique etendue reagissant avec les antigenes du staphylocoque | |
Marcussen | Fluorescent anti-colonic and E. coli antibodies in ulcerative colitis | |
Beachey | Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant | |
US20070269424A1 (en) | Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of moraxella bovis infections | |
WO1996009321A9 (fr) | Anticorps a activite opsonique etendue reagissant avec les antigenes du staphylocoque |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/4-4/4,DRAWINGS,REPLACED BY NEW PAGES 1/5-5/5;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2109088 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992912647 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992912647 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992912647 Country of ref document: EP |